



Available online at
ScienceDirect
www.sciencedirect.com

Elsevier Masson France
EM|consulte
www.em-consulte.com/en



IMAGE

The new place of imaging in cardiology, from diagnosis to treatment



La nouvelle place de l'imagerie en cardiologie, du diagnostic and traitement

Erwan Donal^{a,*}, Stéphane Lafitte^b,
 Catherine Sportouch^c

^a Inserm, LTSI-UMR 1099, University of Rennes, CHU de Rennes, 35000 Rennes, France

^b Université de Bordeaux, CHU de Bordeaux, 33000 Bordeaux, France

^c Clinique du Millénaire, 34000 Montpellier, France

Received 7 March 2019; accepted 18 March 2019

Available online 23 April 2019

KEYWORDS

Imaging;
 Artificial intelligence;
 Heart disease

MOTS CLÉS

Imagerie ;
 Intelligence artificielle ;
 Maladie cardiaque

The world of cardiology has changed, and continues to develop apace. We are moving from medicine based on scientific proofs to personalized medicine [1]. Scientific research is ongoing, and the amount of knowledge required to treat a patient is increasing. We have many specificities to deal with, and some of these patient characteristics come from imaging techniques that are used largely in the field of cardiovascular diseases [2].

New approaches are starting to be applied, which may have a considerable effect on the way we use imaging techniques in the near future [3]. Artificial intelligence is emerging; in fact, machine learning and other statistical approaches that can be grouped under the umbrella of “artificial intelligence” are ubiquitous. Increasingly, these approaches are applied to assist us, especially in the field of imaging [3], which may change practices and decision-making processes significantly.

For the moment, and probably for some time to come, personalized medicine is based essentially on discussion and confrontation within the Heart Team [4,5]. Discussion between specialists, including imaging specialists, is and will continue to be fundamental to ensure good decision-making processes in personalized medicine [6].

This issue of *Archives of Cardiovascular Diseases* emphasizes the relevance of imaging techniques and their use in combination to optimize diagnosis and ultimately to provide patients with the best possible treatment for cardiomyopathies and ischaemic heart disease. As illustrated by the research published in this issue, we are still struggling with non-invasive variables that can best quantify left ventricular function or be used to better characterize filling pressure and prognosis [7,8]. Studies are based on rather small numbers of patients, and imaging specialists often pro-

* Corresponding author at: Service de cardiologie, hôpital Pontchaillou, CHU de Rennes, 35033 Rennes, France.

E-mail address: erwan.donal@chu-rennes.fr (E. Donal).




Figure 1. Combined use of imaging techniques according to clinical needs and local expertise. CMR: cardiac magnetic resonance imaging; CT: computed tomography; Echo: echocardiography; Nuc: nuclear imaging; TOE: transoesophageal echocardiography.

pose pathophysiological concepts and demonstrations. We are less prone to demonstrate the effect of imaging tools on treatment. We know from recommendations and guidelines that much remains to be done to demonstrate that imaging techniques can be robust and key in the decision-making process in, for instance, the field of heart valve disease [9], where new concepts have emerged. We have yet to demonstrate that low-flow low-gradient aortic valve stenosis and preserved ejection fraction is a clinical situation that needs to be considered for percutaneous or surgical aortic valve replacement (after careful evaluation, including echocardiography and, at least, cardiac computed tomography) [10,11]. Also, the recent COAPT and MITRA-FR trials—randomized studies dedicated to the treatment of secondary mitral regurgitation—have provided new concepts, such as that of disproportionate secondary mitral regurgitation [12–14]. Thus, we can highlight how fundamental it is to evaluate heart valve disease correctly using imaging techniques, including assessment of valve anatomy and the impact on the heart chambers, and quantification of regurgitation.

Echocardiography is important, but other imaging techniques must also be considered [12]. As illustrated in Fig. 1, the imaging specialist often starts with transthoracic echocardiography; although this modality provides key data, additional information may be required. The most appropriate tools (exercise stress tests, three-dimensional transoesophageal echocardiography, cardiac computed tomography) must be selected, according to the clinical context. Single-photon emission computed tomography (SPECT), positron emission tomography (PET) and nuclear imaging techniques have great additional value [15].

In addition, of course, cardiac magnetic resonance imaging can be especially helpful for tissue characterization, to help with the diagnosis of many cardiovascular diseases; this imaging tool is also advancing towards characterization and quantification of flows and valvular heart diseases [16].

The combined use of imaging modalities is relevant, not only for cardiovascular diseases, but also for assessing the effects of treatments on the heart, and it is required increasingly in the extensive field of cardio-oncology [17].

There is, therefore, much to be learnt in this issue of *Archives of Cardiovascular Diseases*, but a great deal remains to be explored, in terms of better application of the different imaging techniques to the wide variety of clinical situations that the cardiologist has to deal with.

Acknowledgements

We wish to thank the entire board of the Filiale d'imagerie cardiovasculaire de la Société française de cardiologie.

Disclosure of interest

The authors declare that they have no competing interest.

References

- [1] Califf RM. Future of Personalized Cardiovascular Medicine: JACC State-of-the-Art Review. *J Am Coll Cardiol* 2018;72:3301–9.

- [2] Shameer K, Johnson KW, Glicksberg BS, Dudley JT, Sengupta PP. The whole is greater than the sum of its parts: combining classical statistical and machine intelligence methods in medicine. *Heart* 2018;104:1228.
- [3] Al'Aref SJ, Anchouche K, Singh G, et al. Clinical applications of machine learning in cardiovascular disease and its relevance to cardiac imaging. *Eur Heart J* 2018;27, <http://dx.doi.org/10.1093/eurheartj/ehy404>.
- [4] Habib G, Lancellotti P, Antunes MJ, et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: the European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). *Eur Heart J* 2015;36:3075–128.
- [5] De Bonis M, Al-Attar N, Antunes M, et al. Surgical and interventional management of mitral valve regurgitation: a position statement from the European Society of Cardiology Working Group on Cardiovascular Surgery and Valvular Heart Disease. *Eur Heart J* 2016;37:133–9.
- [6] Sardari Nia P, Heuts S, Daemen J, et al. Preoperative planning with three-dimensional reconstruction of patient's anatomy, rapid prototyping and simulation for endoscopic mitral valve repair. *Interact Cardiovasc Thorac Surg* 2017;24:163–8.
- [7] Hubert A, Le Rolle V, Leclercq C, et al. Estimation of myocardial work from pressure-strain loops analysis: an experimental evaluation. *Eur Heart J Cardiovasc Imaging* 2018;19:1372–9.
- [8] Frikha Z, Girerd N, Huttin O, et al. Reproducibility in echocardiographic assessment of diastolic function in a population based study (the STANISLAS Cohort study). *PLoS One* 2015;10:e0122336.
- [9] Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. *Eur Heart J* 2017;38:2739–91.
- [10] Clavel MA, Burwash IG, Pibarot P. Cardiac Imaging for Assessing Low-Gradient Severe Aortic Stenosis. *JACC Cardiovasc Imaging* 2017;10:185–202.
- [11] Dahou A, Clavel MA, Dumesnil JG, et al. Impact of AVR on LV Remodeling and Function in Paradoxical Low-Flow, Low-Gradient Aortic Stenosis With Preserved LVEF. *JACC Cardiovasc Imaging* 2017;10:88–9.
- [12] Grayburn PA, Sannino A, Packer M. Proportionate and Disproportionate Functional Mitral Regurgitation: A New Conceptual Framework That Reconciles the Results of the MITRA-FR and COAPT Trials. *JACC Cardiovasc Imaging* 2019;12:353–62.
- [13] Obadia JF, Messika-Zeitoun D, Leurent G, et al. Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation. *N Engl J Med* 2018;379:2297–306.
- [14] Stone GW, Lindenfeld J, Abraham WT, et al. Transcatheter Mitral-Valve Repair in Patients with Heart Failure. *N Engl J Med* 2018;379:2307–18.
- [15] Hagege A, Reant P, Habib G, et al. Fabry disease in cardiology practice: Literature review and expert point of view. *Arch Cardiovasc Dis* 2019;112(4):278–87, <http://dx.doi.org/10.1016/j.acvd.2019.01.002> [Epub 2019 Feb 28].
- [16] Kammerlander AA, Wiesinger M, Duca F, et al. Diagnostic and Prognostic Utility of Cardiac Magnetic Resonance Imaging in Aortic Regurgitation. *JACC Cardiovasc Imaging* 2018, <http://dx.doi.org/10.1016/j.jcmg.2018.08.036>.
- [17] Escudier M, Cautela J, Malissen N, et al. Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity. *Circulation* 2017;136:2085–7.